natgillin/translations-raw huggingface dataset:
Of the 326 (38%) patients with reports of adverse reactions of thrombocytopenia, 29 (9%) patients discontinued treatment with bosutinib due to thrombocytopenia.
Od 326 (38 %) bolnikov, pri katerih so poročali o neželenem učinku trombocitopeniji, jih je 29 (9 %) prekinilo z jemanjem bosutiniba zaradi trombocitopenije.
Of the 35 cases where medical history was provided, in 25 there was a history of bronchoconstrictive disease (asthma, COPD or bronchospasm) and in 10 there was no documented history of bronchoconstrictive disease, including 3 cases where the reporter explicitly stated that there was no history of asthma/bronchospasm/COPD.
Od 35 primerov, v katerih je bila na voljo anamneza, je ta v 25 primerih vključevala bronhokonstriktorne bolezni (astma, KOPB ali bronhospazem) in v 10 primerih ni bilo dokumentirane anamneze bronhokonstriktornih bolezni, vključno s 3 primeri, v katerih je poročevalec izrecno navedel, da v anamnezi ni astme/bronhospazma/KOPB.
Of the 361 women who received atosiban treatment in the phase III studies, 73 received at least one re- treatment, 8 received at least 2 re-treatments and 2 received 3 re-treatments (see section 4.4).
Od 361 žensk, zdravljenih z atosibanom v študijah III. faze, je bilo zdravljenje ponovljeno vsaj enkrat pri 73 ženskah, vsaj dvakrat pri 8 ženskah, vsaj trikrat pa pri 2 ženskah (glejte poglavje 4.4).
Of the 361 women who received atosiban treatment in the phase III studies, 73 received at least one re-treatment, 8 received at least 2 re-treatments and 2 received 3 re-treatments (see section 4.4).
Od 361 žensk, zdravljenih z atosibanom v študijah III. faze, je bilo zdravljenje ponovljeno vsaj enkrat pri 73 ženskah, vsaj dvakrat pri 8 ženskah, vsaj trikrat pa pri 2 ženskah (glejte poglavje 4.4).
Of the 39 patients who had received two or more prior induction regimens, 5 (13 %) [95 % CI: 4 %– 27 %] achieved a complete response (bone marrow blast counts ≤ 5 %, no other evidence of disease, and full recovery of peripheral blood counts) and 9 (23 %) [95 % CI: 11 %–39 %] achieved complete responses with or without full haematological recovery.
Od 39 bolnikov, ki so se predhodno zdravili z dvema ali več indukcijskimi režimi zdravljenja, je bil pri 5 (13 %) [95 % interval zaupanja: 4 %–27 %] dosežen popolni odziv (delež blastov v kostnem mozgu ≤ 5 %, brez drugih znakov bolezni in izboljšanje periferne krvne slike v celoti), pri 9 (23 %) [95 % interval zaupanja: 11 %–39 %] pa popolni odziv s hematološkim izboljšanjem ali brez njega.
Of the 39 placebo subjects, 29 completed 24 months of treatment with Revestive.
Od 39 preiskovancev, ki so prejemali placebo, jih je 29 zaključilo 24-mesečno zdravljenje z zdravilom Revestive.
Of the 392 patients randomised, 76.3% were naïve to prior VEGF/VEGFR-targeted therapies, 49.0% were female, 49.7% were European, and the median age was 63 years.
392 randomiziranih bolnikov jih 76,3 % nikoli prej ni prejemalo zdravljenja, usmerjenega v VEGF/VEGFR, 49,0 % jih je bilo ženskega spola, 49,7 % je bilo Evropejcev, mediana starost pa je bila 63 let.
Of the 4,204 plaque psoriasis patients exposed to Taltz in clinical studies, a total of 301 were 65 years of age or older and 36 patients were 75 years of age or older.
Od 4204 bolnikov s psoriazo s plaki, ki so bili izpostavljeni zdravilu Taltz v kliničnih študijah, je bilo skupaj 301 bolnik star 65 let ali več, 36 bolnikov pa je bilo starih 75 let ali več.
Of the 403 patients who received CRESEMBA in the Phase 3 studies, 79 (20%) of patients had an estimated glomerular filtration rate (GFR) less than 60 mL/min/1.73 m2.
Od 403 bolnikov, ki so prejemali zdravilo CRESEMBA v študiji 3. faze, je imelo 79 (20 %) bolnikov ocenjeno hitrost glomerulne filtracije (GFR) niţjo od 60 ml/min/1,73 m2.
Of the 418 patients treated with Caelyx 50 mg/m2/cycle, and having a baseline measurement of left ventricular ejection fraction (LVEF) and at least one follow-up measurement assessed by MUGA scan, 88 patients had a cumulative anthracycline dose of > 400 mg/m2, an exposure level associated with an increased risk of cardiovascular toxicity with conventional doxorubicin.
Pri 418 bolnikih, zdravljenih z zdravilom Caelyx v odmerku 50 mg/m2 na cikel, pri katerih so opravili meritev vrednosti iztisnega deleža levega prekata na začetku raziskave in vsaj eno kontrolno meritev s slikanjem MUGA, jih je 88 prejelo kumulativni odmerek antraciklina > 400 mg/m2- to je količina, ki je bila pri standardnih pripravkih doksorubicina povezana z večjim tveganjem za pojav kardiovaskularne toksičnosti.
Of the 46 patients (1.6%) who developed anti-tocilizumab antibodies, 6 had an associated medically significant hypersensitivity reaction, of which 5 led to permanent discontinuation of treatment.
Od 46 bolnikov (1,6 %), pri katerih so se pojavila protitelesa proti tocilizumabu, jih je 6 imelo spremljajočo klinično pomembno preobčutljivostno reakcijo, ki je v 5 primerih vodila v ukinitev zdravljenja.
Of the 496 patients exposed to Kentera in the randomised, double-blind, placebo-controlled 12-week study and the 14-week safety extension study, 188 patients (38%) were 65 years of age and older.
Med 496 bolniki, ki so v randomizirani, dvojno slepi, s placebom nadzorovani 12-tedenski študiji in 14- tedenski podaljšani študiji varnosti bili izpostavljeni zdravilu Kentera, je bilo 188 bolnikov (38 %) starih 65 let ali več.
Of the 5 cases reported, 3 were associated with excessive alcohol intake, 1 was associated with biliary sludge, and in one case the patient discontinued eluxadoline 2 weeks prior to the onset of symptoms.
Med 5 opisanimi primeri so bili 3 povezani s čezmernim uživanjem alkohola, eden je bil povezan z nastankom oborin v žolčniku in v enem primeru je bolnik prekinil uporabo eluksadolina 2 tedna pred nastopom simptomov.
Of the 511 patients receiving ofatumumab in clinical trials, 300 patients (59%) experienced an infection.
Od 511 bolnikov, ki so prejemali ofatumumab v kliničnih študijah, se je 300 bolnikom (59 %) pojavila okužba.
Of the 52 patients described above that were included in Study CAC-91-10-10 during the 17-year study period, 6 died, 3 had no evidence of treatment, 4 terminated the study, 10 were lost to follow-up, and for 1 data retrieval was unsuccessful.
Od 52 bolnikov, opisanih zgoraj, vključenih v študijo CAC-91-10-10 v 17-letnem obdobju študije, jih je šest umrlo, trije niso imeli nobenih dokazov zdravljenja, štirje so prekinili študijo, deset jih ni opravilo sledenja, pri enem pa je bilo pridobivanje podatkov neuspešno.
Of the 52 patients described above that were included in Study CAC-91-10-10 during the 17-year study period, 6 died, 3had no evidence of treatment, 4 terminated the study, 10 were lost to follow-up, and for 1 data retrieval was unsuccessful.
Od 52 bolnikov, opisanih zgoraj, vključenih v študijo CAC-91-10-10 v 17-letnem obdobju študije, jih je šest umrlo, trije niso imeli nobenih dokazov zdravljenja, štirje so prekinili študijo, deset jih ni opravilo sledenja, pri enem pa je bilo pridobivanje podatkov neuspešno.
Of the 52 patients identified, 36 patients were in the CP CML subpopulation (21 who had previously received 2 prior TKIs and 15 who had received 1 prior TKI).
Od 52 identificiranih bolnikov jih je bilo 36 v podpopulaciji s KML v kronični fazi (od tega jih je 21 predhodno prejemalo po 2 TKI, 15 pa po 1 TKI).
Of the 54 patients withdrawn from ORENCIA during the double-blind period for up to 6 months, none had an infusion reaction upon re-initiation of ORENCIA.
Pri nobenem od 54 bolnikov, pri katerih je bilo zdravljenje z zdravilom ORENCIA med dvojno slepim obdobjem prekinjeno za do 6 mesecev, se po ponovni uvedbi zdravljenja z zdravilom ORENCIA ni pojavila infuzijska reakcija.
Of the 571 ankylosing spondylitis patients exposed to Cosentyx in clinical studies, a total of 24 patients were 65 years of age or older and 3 patients were 75 years of age or older.
Med 571 bolniki z ankilozirajočim spondilitisom, ki so bili v kliničnih študijah izpostavljeni zdravilu Cosentyx, je bilo skupno 24 bolnikov starih 65 let ali več, 3 bolniki pa so bili stari 75 let ali več.
Of the 6026 total number of patients in clinical studies of Repatha, 1779 (30%) were ≥ 65 years old, while 223 (4%) were ≥ 75 years old.
Od skupaj 6.026 bolnikov v kliničnih študijah zdravila Repatha je bilo 1.779 (30 %) starih ≥ 65 let, 223 (4 %) pa ≥ 75 let.
Of the 611 patients treated with the ZALTRAP/FOLFIRI regimen in the pivotal study of MCRC patients, 172 (28.2%) were aged ≥65 and <75 and 33 (5.4%) were age ≥75.
Od 611 bolnikov, zdravljenih s shemo ZALTRAP/FOLFIRI v ključni študiji pri bolnikih z mKRR, je bilo 172 (28,2 %) starih od ≥ 65 do < 75 let, 33 (5,4 %) pa je bilo starih ≥ 75 let.
Of the 681 (78%) patients that experienced diarrhoea, 665 patients had drug-related events of diarrhoea and 8 patients discontinued bosutinib due to this event.
Od 681 (78 %) bolnikov, ki so imeli diarejo, jih je 665 imelo z zdravilom povezan nastanek diareje in 8 bolnikov je zaradi diareje prekinilo zdravljenje z bosutinibom.
Of the 7 patients who deteriorated at week 8, 3 improved at week 12/16 and 4 deteriorated compared with baseline.
Od 7 bolnikov s poslabšanjem stanja v 8. tednu se je pri 3 bolnikih stanje izboljšalo v 12./16. tednu, pri 4 bolnikih pa se je stanje v primerjavi z izhodiščnim stanjem poslabšalo.
Of the 7 patients who deteriorated at week 8, 3 improved at week 12/16 and 4 deteriorated compared with baseline.
Od 7 bolnikov s poslabšanjem stanja v 8. tednu, se je pri 3 bolnikih stanje izboljšalo v 12./16. tednu, pri 4 bolnikih pa se je stanje v primerjavi z izhodiščnim stanjem poslabšalo.
Of the 704 patients evaluated in the MM-009 and MM-010 studies, 44.6% were aged 65 or over.
Od 704 bolnikov, ki so jih ocenili v študijah MM-009 in MM-010, je bilo 44,6% bolnikov starih 65 let ali več.
Of the 72 patients randomised to Cosentyx 150 mg, 45 and 35 had an ASAS 20/40 response, respectively.
Med 72 bolniki, ki so bili randomizirani na prejemanje zdravil Cosentyx 150 mg, jih je 45 oziroma 35 doseglo odziv ASAS 20 oziroma ASAS 40.
Of the 760 randomised patients, the median age was 61 years, 61% were male, 78% were Caucasian, and all patients had baseline ECOG Performance Status (PS) of 0 or 1.
Med 760 randomiziranimi bolniki je bila mediana starost 61 let, 61 % je bilo moških, 78 % je bilo belcev in vsi bolniki so imeli izhodiščni status zmogljivosti (PS - Performance Status) po ECOG 0 ali 1.
Of the 783 patients initially randomised to active treatment in RA-I, 508 completed 52 weeks of placebo- controlled treatment and entered the open-label extension study.
Od 783 bolnikov, ki so bili na začetku randomizirano izbrani za aktivno zdravljenje v študiji RA-I, jih je 508 zaključilo 52-tedensko s placebom nadzorovano zdravljenje in vstopilo v odprt podaljšek študije.
Of the 87 patients treated with Epclusa + RBV, 85 patients were included in the analysis of NS5A RAVs; 2 patients were excluded as they neither achieved SVR12 nor had virologic failure.
Od 87 bolnikov, ki so prejemali zdravljenje z zdravilom Epclusa + RBV, je bilo 85 bolnikov vključenih v analizo RAV NS5A; 2 bolnika sta bila izključena, ker nista dosegla niti SVR12 niti virološkega neuspeha.
Of the 94 patients with cirrhosis at baseline (Ishak fibrosis score: 5 - 6), 26% (24) experienced no change in Ishak fibrosis score and 72% (68) experienced regression of cirrhosis by week 240 with a reduction in Ishak fibrosis score of at least 2 points.
Od 94 bolnikov s cirozo ob izhodiščni točki (stopnja fibroze po Ishak-u: 5 – 6) jih 26% (24) ni doživelo spremembe v stopnji fibroze po Ishak-u in 72% (68) je doživelo nazadovanje ciroze do 240. tedna z zmanjšanjem stopnje fibroze po Ishak-u za vsaj 2 točki.
Of the 97 aMCI patients who had a positive PET scan and at least one committee assessment, 52 (54%) were classified clinically as converted to clinical AD after 36 months compared to 29 (23%) of 127 who had a negative scan and at least one committee assessment.
Od 97 bolnikov z diagnozo aMCI, pri katerih je bila PET slika pozitivna in so imeli vsaj eno oceno neodvisne komisije, jih je bilo 52 (54 %) klinično ocenjenih s spremenjeno diagnozo v AB po 36 mesecih, v primerjavi z 29 (23 %) od 127 bolnikov, pri katerih je bila slika negativna in so imeli vsaj eno oceno neodvisne komisije.
Of the 974 psoriatic arthritis patients exposed to Cosentyx in clinical studies, a total of 85 patients were 65 years of age or older and 4 patients were 75 years of age or older.
Med 974 bolniki s psoriatičnim artritisom, ki so bili v kliničnih študijah izpostavljeni zdravilu Cosentyx, je bilo skupno 85 bolnikov starih 65 let ali več, 4 bolniki pa so bili stari 75 let ali več.
Of the 981 patients treated with IMBRUVICA, 62% were 65 years of age or older.
Med 981 bolniki, zdravljenimi z zdravilom IMBRUVICA, jih je bilo 62% starih 65 let ali več.
Of the circulating metabolites, the majority are glucuronide conjugates of posaconazole with only minor amounts of oxidative (CYP450 mediated) metabolites observed.
Od presnovkov v obtoku je večina glukuronidnih konjugatov posakonazola, opazili pa so le majhne količine oksidativnih presnovkov (presnova posredovana s CYP450).
Of the enrolled patients, 22% had stage IV M1c disease and 53% of patients had received prior therapy for melanoma such as chemotherapy and cytokine-based immunotherapy in addition to surgery, adjuvant therapy or radiation.
Od zajetih bolnikov jih je 22 % imelo bolezen v stadiju IV M1c; 53 % bolnikov je predhodno že prejemalo zdravljenje za melanom, kot je kemoterapija in imunoterapija s citokini, poleg kirurškega posega, adjuvantnega zdravljenja ali obsevanja.
Of the hepatic AEs, increased ALT and AST were the most common events and the majority were either Grade 1 or 2.
Med jetrnimi neželenimi dogodki sta bila najpogostejša zvišanje vrednosti ALT in AST, pri čemer je bila večina zvišanj 1. ali 2. stopnje.
Of the HIV-1 isolates from 8 patients with resistance development in the E/C/F/TDF group, the mutations that emerged were M184V/I (n = 6) and K65R/N (n = 3) in RT and E92E/Q (n = 2), and Q148R (n = 2), and N155H/S (n = 2) in integrase.
Pri izolatih HIV-1 pri 8 bolnikih z razvojem rezistence v skupini E/C/F/TDF so se pojavile mutacije M184V/I (n = 6) in K65R/N (n = 3) v RT ter E92E/Q (n = 2) in Q148R (n = 2) in N155H/S (n = 2) v integrazi.
Of the individuals taking Truvada, 0.8% (13 out of 1,576) tested positive for HIV-1 infection over 1 year compared with 3.3% (52 out of 1,578) of those taking placebo.
Med tistimi, ki so jemali zdravilo Truvada, je bilo v enem letu testiranje za okužbo z virusom HIV-1 pozitivno pri 0,8 % (13 od 1 576) v primerjavi s 3,3 % (52 od 1 578) tistih, ki so jemali placebo.
of the infection, the
huda je okužba, od
Of the infliximab- treated patients who received at least one shortened infusion, infusion-related reactions occurred in 15% of patients and serious infusion reactions occurred in 0.4% of patients.
Pri bolnikih, zdravljenih z infliksimabom, ki so prejeli najmanj eno skrajšano infuzijo, so se z infuzijo povezane reakcije pojavljale pri 15 % bolnikov, resne z infuzijo povezane reakcije pa pri 0,4 % bolnikov.
Of the most commonly reported, the following events occurred more often with Ranexa (placebo-corrected frequencies) in elderly ( 75 years of age) than younger patients (< 75 years of age): constipation (8% versus 5%), nausea (6% versus 3%), hypotension (5% versus 1%), and vomiting (4% versus 1%).
Med neželenimi dogodki, o katerih so poročali najpogosteje, so ob jemanju zdravila Ranexa naslednji bili pogostejši (pogostnost pri placebu je odšteta) pri starejših ( 75 let) kot pri mlajših (< 75 let) bolnikih: obstipacija (8 % v primerjavi s 5 %), navzea (6 % v primerjavi s 3 %), hipotenzija (5 % v primerjavi z 1 %) in bruhanje (4 % v primerjavi z 1 %).
Of the need for the procedures/tests before and during teriflunomide treatment
da je treba pred uvedbo zdravljenja s teriflunomidom in med njim opravljati preiskave / teste
Of the patients randomised to the chemotherapy arm, 48% crossed over and subsequently received treatment with pembrolizumab.
Terapevtski prehod je bil narejen pri 48 % bolnikov, randomiziranih na kemoterapijo; ti bolniki so nato prejemali zdravljenje s pembrolizumabom.
Of the patients who achieved at least a 20% reduction of parenteral nutrition at Weeks 20 and 24 in the initial study, 75% sustained this response on Revestive after up to 1 year of continuous treatment.
Od bolnikov, ki so dosegli vsaj 20 % zmanjšanje parenteralne prehrane po 20 in 24 tednih začetne študije, jih je 75 % vzdrževalo takšen odziv ob neprekinjenem zdravljenju z zdravilom Revestive do 1 leto.
Of the patients who achieved CCyR, 85% (95% CI: 78% - 93%) were maintaining response at 24 months.
Med bolniki, pri katerih je prišlo do popolnega citogenetičnega odziva, se je pri 85 % (95- odstotni IZ: 78 % - 93 %) odziv po 24 mesecih ohranil.
Of the patients who completed the study who were originally randomised to placebo + MTX, 86% received open-label tocilizumab 8 mg/kg in year 2.
Od bolnikov, ki so zaključili študijo, in ki so bili na začetku randomizirani v skupino s placebom ter metotreksatom, jih je 86 % prejemalo odprto zdravljenje s tocilizumabom 8 mg/kg v 2. letu.
Of the patients who did not meet stability criteria for the individual components, 12 of 15 Cerdelga patients and 3 of 3 Cerezyme patients remained within therapeutic goals for GD1.
Od bolnikov, ki niso dosegali meril stabilnosti za posamezne elemente, jih je 12 od 15, ki so prejemali zdravilo Cerdelga, in 3 od 3, ki so prejemali zdravilo Cerezyme, ostalo znotraj meja ciljev zdravljenja za GD1.
Of the patients who had been clinically diagnosed with MCI at study entry, 9 (19%) converted to clinical AD 36 months later.
Od bolnikov, ki so imeli ob vstopu v študijo klinično diagnozo zmerne kognitivne okvare, jih je 36 mesecev pozneje 9 (19 %) prešlo v klinično AB.
Of the patients who lost adequate response after re-randomization to placebo who then enrolled into the open-label extension trial, 38% (25/66) and 55% (36/66) regained PASI 75 response after 12 and 24 weeks of re-treatment, respectively.
Med bolniki, ki so izgubili ustrezen odziv ob ponovni randomizaciji na placebo med podaljšanim odprtim preskušanjem, je po 12 tednih ponovne terapije PASI 75 znova doseglo 38 % (25/66), po 24 tednih pa 55 % (36/66) bolnikov.
Of the patients who received nivolumab, the ORR in the BRAF mutation-positive subgroup (n=26) was 23% (95% CI: 9.0, 43.6), and 34% (95% CI: 24.6, 44.5) in patients whose tumours were BRAF wild-type (n=94).
Pri bolnikih, ki so prejemali nivolumab, je delež objektivnega odziva v podskupini z mutacijo BRAF (n=26) znašal 23 % (95 % interval zaupanja: 9,0; 43,6), pri bolnikih, ki so imeli tumor z divjim tipom BRAF (n=94) pa 34 % (95 % interval zaupanja: 24,6; 44,5).
Of the patients who received Simponi, 59% (82 out of 138) had 20% reductions after 14 weeks, compared with 22% of patients who were given placebo (17 out of 78).
Pri bolnikih, ki so jemali zdravilo Simponi, je po 14 tednih prišlo do 20-odstotnega zmanjšanja pri 59 % (82 od 138 bolnikov) v primerjavi z 22 % (17 od 78) bolnikov, ki so jemali placebo.
of the plasma levels of lopinavir is
koncentracijo lopinavirja v plazmi
of the plasma levels of saquinavir is
koncentracijo sakinavirja v plazmi
Of the randomised patients, 44.9 % had a complete/partial response and 51.9 % had a response of stable disease to pemetrexed plus cisplatin induction.
Izmed naključno izbranih bolnikov jih je 44,9 % doseglo popoln/delen odziv in 51,9 % jih je doseglo odziv stabilne bolezni na pemetreksedin indukcijsko zdravilo cisplatina.
Of the randomised patients, 44.9% had a complete/partial response and 51.9% had a response of stable disease to pemetrexed plus cisplatin induction.
Izmed naključno izbranih bolnikov jih je 44,9% doseglo popoln/delen odziv, 51,9% jih je doseglo odziv stabilne bolezni na pemetreksed in indukcijsko zdravilo cisplatina.
of the reductions in
farmakokinetičnih
Of the rheumatoid arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed new positive ANA (≥ 1:40) was higher in patients treated with etanercept (11%) than in placebo- treated patients (5%).
Pri bolnikih z revmatoidnim artritisom, ki so jih testirali na antinuklearna protitelesa (ANA), je bil odstotek tistih, ki so razvili nova pozitivna ANA (≥ 1:40), večji pri bolnikih, ki so prejemali etanercept (11 %), kot pri tistih, ki so prejemali placebo (5 %).
Of the rheumatoid arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed new positive ANA (1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated patients (5%).
Pri bolnikih z revmatoidnim artritisom, ki so jih testirali na antinuklearna protitelesa (ANA), je bil odstotek tistih, ki so razvili nova pozitivna ANA ( 1:40), večji pri bolnikih, ki so prejemali zdravilo Enbrel (11 %), kot pri tistih, ki so prejemali placebo (5 %).
OF THE SIGHT AND REACH OF CHILDREN
POGLEDA OTROK
OF THE SIGHT AND REACH OF CHILDREN
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN POGLEDA OTROK
Of the specimens from the non-clinical and clinical studies (n = 876) that were mutation positive by the THxID BRAF assay and subsequently were sequenced using the reference method, the specificity of the assay was 94%.
Na vzorcih predkliničnih in kliničnih študij (n = 876), ki so imele s testom ThxID določeno mutacijo BRAF in so bili nato sekvencirani z referenčno metodo, je bila specifičnost testa 94 %.
Of the specimens from the non-clinical and clinical studies (n=876) that were mutation positive by the THxID BRAF assay and subsequently were sequenced using the reference method, the specificity of the assay was 94%.
Na vzorcih predkliničnih in kliničnih študij (n = 876), ki so imeli s testom ThxID določeno mutacijo BRAF in so bili nato sekvencirani z referenčno metodo, je bila specifičnost testa 94 %.
Of the subjects with observed data at Week 16 in the four Phase 3 clinical trials, 50.8% of those randomized to receive naltrexone / bupropion had lost ≥5% of their baseline body weight, compared to 19.3% of placebo-treated subjects (Week 16 Responders).
Od preiskovancev, pri katerih so preverili podatke v 16. tednu v štirih kliničnih preskušanjih 3. faze, je 50,8 % tistih, ki so bili randomizirani za prejemanje naltreksona/bupropiona, zmanjšalo svojo izhodiščno telesno maso za ≥5 % v primerjavi z 19,3 % preiskovancev, ki so prejemali placebo (odzivni preiskovanci 16. tedna).
Of the total 123 patients, 26 patients died; each of these deaths could be attributed either as a complication of the index event or associated with co-morbidities.
Od skupno 123 bolnikov jih je umrlo 26; vsako izmed teh smrti lahko pripišemo bodisi komplikaciji zdravljenega dogodka ali povezanosti s sočasnimi obolenji.
Of the total 128 patients who entered part I taking corticosteroids, 92 attempted corticosteroid tapering.
Izmed skupno 128 bolnikov, ki so ob vstopu v 1. obdobje jemali kortikosteroide, jih je 92 poskušalo postopno ukiniti zdravljenje z njimi.
Of the total 25 subjects: 9 received placebo, 9 received mepolizumab 75 mg intravenously, and 7 received 100 mg subcutaneously.
Od skupno 25 preiskovancev jih je 9 dobivalo placebo, 9 jih je dobivalo 75 mg mepolizumaba intravensko in 7 jih je dobivalo 100 mg subkutano.
Of the total maltol ingested, a mean of between 39.8 % and 60.0 % was excreted as maltol glucuronide.
Od skupnega zaužitega maltola se je v obliki maltolovega glukuronida povprečno izločilo med 39,8 % in 60,0 %.
Of the total number of patients in clinical studies of dabrafenib (N=578), 22% were 65 years of age and older, and 6% were 75 years of age and older.
Od celotnega števila bolnikov v kliničnih študijah dabrafeniba (N = 578) je bilo 22 % starih 65 let ali več in 6 % 75 let ali več.
Of the total number of patients in clinical studies of osimertinib (N=411), 46% were 65 years of age and older, of whom 13% were 75 years of age and older.
Od celotnega števila bolnikov v kliničnih študijah osimertiniba (n = 411) je bilo 46 % starih 65 let ali več in 13 % je bilo starih 75 let ali več.